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Assessment of major histocompatibility complex 
class I interaction with Epstein-Barr virus and 
human immunodeficiency virus peptides by 
elevation of membrane H-2 and HLA in peptide 
loading-deficient cells* 
Earlier findings indicate that peptides can affect the expression of major 
histocompatibility complex (MHC) class I molecules on the surface of cells with 
defective peptide loading mechanism. We have used peptide induced increase of 
class I antigen expression to assess peptide interaction with MHC class I 
molecules. A panel of 41 overlapping synthetic peptides derived from the human 
immunodeficiency virus-1 (HIV-1) gag protein and 33 nonoverlapping peptides 
from Epstein-Barr virus (EBV) proteins EBNA-1, 2, 3, 4, 5 ,  6, LMP, BZLF2, 
BILF2, BSLF2, BALF4 and BcLFl was assessed for the ability to enhance the 
expression of HLA-A2.1, H-2Db, Kh and Dd on the murine RMA-S and human 
721.174/T2 (. 174/T2) lines by indirect immunofluorescence. Considering doub- 
ling of the fluorescence intensity in the peptide-treated samples as positivity, 6 of 
39 HIVand 1 of 32 EBVpeptides were found to bind to A2.1,6 of 39 HIVgag and 
7 of 16 EBVpeptides to Dh, 8 of 39 HIVgag and 5 of 16 EBV peptides to Kb and 2 
of 39 HIV gag and 1 of 17 EBV peptides to Dd. The sensitivity of the method is 
comparable to the in vitro class I assembly assay with conformation-dependent 
monoclonal antibody and is more discriminating than the solid-phase assay. Due 
to its simplicity this method can also serve for testing large peptide panels for 
binding capacity to various class I molecules. Moreover, the method provides 
information about the relevance of in vitro tests for class I assembly in living 
cells. 
1 Introduction 
Major histocompatibility complex (MHC) class I molecules 
present endogenously processed peptides to cytotoxic 
T cells [ 1, 21. Using solid-phase binding assay several 
authors reported indiscriminative binding of peptides to 
different class I moleculeo [3-51. However, both the quan- 
titative class I assembly assay with conformation-depen- 
dent mAh [6] and the photoaffinity labeling technique [7] 
have revealed specific peptide binding to MHC class I 
molecules. Similarly, distinct subsets of peptides were 
shown to bind to HLA-A2.1 and HLA-B37, respectively, 
by the peptide competition assay [8]. 
Previously our group has developed an MHC class I- 
deficient variant subline, RMA-S of the Rauscher virus- 
induced T cell lymphoma, RBL-5 (H-2”) [9]. Assembly and 
expression of MHC class I could be enhanced by adding 
influenza peptides with specific affinity for H-2 Db and Kh 
(10, 111. This suggests that peptide binding is required for 
the effective assembly or for the stability of class I mole- 
cules. The peptide/H-2 allele specific induction of cell 
surface MHC class I molecules could then be explained in 
two different ways (a) pinocytosis of peptides into the cells 
and induction of MHC class I assembly at an intracellular 
location, leading to an elevated number of transport 
component molecules [ l l ]  or [6] binding of peptides to the 
few empty MHC class I 62 microglobulin heterodimers that 
reach the cell surface, which would normally turn over 
rapidly at 37”C, but are now stabilized and allowed to 
accumulate [12]. Both of these mutually not exclusive 
mechanisms may contribute to specific induction of MHC 
class I expression in “peptide feeding” experiments. Later, 
similar findings were made on class I expression-deficient 
human LCL .174 and its hybrid derivative .174/T2 [13, 
141. 
We have explored the ability of peptides with affinity to 
given MHC class I molecules to enhance their surface 
expression by measuring the elevation of MHC class I on 
RMA-S and .174/T2 cells after incubation with peptide.We 
have screened a panel of 41 overlapping peptides derived 
from the HIV-1 gag protein and 33 nonoverlapping pep- 
tides derived from the EBVproteins EBNA-1,2,3,4,5,6,  
LMP, BZLF2, BILF2, BSLF2, BALF4 and BcLFl for 
MHC class I induction on RMA-S and .174/T2 cells. 
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2 Materials and methods 
2.1 Cell lines 
RMA-S is a low H-2 expressor mutant of the Rauscher 
virus-induced T cell lymphoma RBL-5 of C57BL/6 (H-2h) 
origin [9]. Full H-2” expression can be induced by adding 
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H-2h affine peptides or incubating the cells at low temper- 
ature [lo-121. It is resistant to CTL specific for internally 
processed antigens 1151. The antigen-processing defect 
could be corrected by the transfection of the ATP- 
dependent transport protein gene HAM-2 into the RMA-S 
cells [16]. The H-2 Dd gene, when transfected into RMA-S 
cells was subject to the same peptide loading defect as the 
endogenous H-2h molecule, and could be up-regulated by 
appropriate peptides or low temperature in a similar way 
(Franksson et al., to be published).The .174/T2 hybrid line 
was kindly provided by Dr. P. Cresswell, Howard Hughes 
Medical Institute, Section of Immunobiology,Yale Univer- 
sity School of Medicine, New Haven, CT. It was derived by 
fusion of the .174 mutant LCL and the CEMR T lymphoma 
and selected for the loss of chromosome 6 of CEMR as 
described [17-211. It does not express B5 and its HLA-A2.1 
expression is about 70%-80% lower than that of the 
wild-type LCL 721. Its peptide loading deficiency is most 
probably due to the deletion of the RING4 and RING11 
genes [22]. 
2.2 Indirect immunoflnorescence assay for MHC-peptide 
interaction and monoclonal antibodies 
Aliquots of 2.5 x los RMA-S or .174/T2 cells were 
incubated with peptide in 250 pl RPMI 1640 for 24 h at 
37°C. The final peptide concentration was 100 p ~ .  MHC 
clas  1 levels were detected by indirect immunofluores- 
cence using FACS IV (Becton Dickinson, Mountain View, 
CA). The results were calculated on the basis of fluores- 
cence intensity (FI), FIvalnplc : FIcontrol, where sample means 
peptide-treated cells and control means cells without 
peptide. 
Living cells were stained for MHC class I antigens by 
indirect immunotluorescence. The first layer was the 28- 
14-8s (anti H-2 Db, mouse I g G p  1231, the 28-13-3s anti Kb, 
mouse IgM [24], the 34-5-8s anti H-2 Dd, mouse IgGz,x 1251 
or the BB7.2 anti HLA-A2 a1 domain, mouse IgGzb [26]. 
All the reagents were culture supernatants of hybridomas 
obtained from American Type Culture Collection (Rock- 
ville, MD), used at 10-15 pg/ml. The second layer was a 
fluorescein isothiocyanate (F1TC)-labeled affinity-purified 
rabbit anti-mouse antibody (Sigma, Saint Louis, MO) at a 
1 : 20 dilution. Samples were analyzed by cytofluorimetry 
using a fluorescence-activated cell sorter (FACS IV, Becton 
Dickinson). 
2.3 Peptide synthesis 
A series of 41 peptides spanning the HIV-1 gag polyprotein 
precursor molecule were synthesized. The peptides are 24 
amino acids (aa) long (with the exception of the 22-23 aa 
long peptides 1,14,15,17 and 25 aa long peptide 27 and 30) 
ovcrlap in 12 (in some cases 11 or 13) aa with both 
neighboring peptides (Table 1). In addition, 33 peptides 
derived from the EBV-encoded proteins EBNA-1,2, 3, 4, 
5, 6, LMP, BZLF2, BILF2, BSLF2, BALF4 and BcLFl 
LMP (Table2) were synthesized. The majority of the 
peptides derived from EBV-encoded proteins were origi- 
nally synthesized in order to produce monospecific anti- 
peptide sera to identify the corresponding EBV gene 
products in Western blots or similar immunoassays. The 
peptides derived from EBNA-3 (aa334-346 and 339-352) 
have been identified as human T cell epitopes in advance 
1271. 
HIV-1 gag and EBNA-1 C term., EBNA-2a, EBNA- 
3/EBV.1, EBNA2-EBV.2, Lydma-l,4, and 5 and the EBV 
lytic cycle protein peptides (Table 2) were synthesized with 
a 9050 Pepsynthesizer (Milligen. Eschborn, FRG) using 
Fmoc (9-fluorenylmethyloxycarbonyl)-protected amino 
acids as described earlier 128, 291. The peptides were 
lyophylized and purified by reverse-phase high-perfor- 
mance liquid chromatography (HPLC) using a C2/C18 
copolymer column (Peps, Pharmacia, Freiburg, FRG) and 
a gradient of 0%-70% acetonitrileF in 0.1% trifluoroacetic 
acid. The peptide containing fractions were lyophilized and 
characterized by amino acid sequencing (Applied Biosys- 
tems, Weiterstedt, FRG). Peptides 68, 68b, 77 and KEH- 
VIQNAFRK, kindly provided by Dr. D. Moss, Queensland 
Institute of Medical Research, Brisbane, Australia, were 
synthesized as described earlier 1301. The remaining EBV 
peptides were synthesized using t-Boc amino acids (Ba- 
chem, Bubendorf, Switzerland) and p-methylbenzhydryl- 
amine resin (Fluka, Buchs, Switzerland) according to the 
multiple solid-phase peptide synthesis method as described 
earlier 130-321 kindly provided by Dr. J. Dillner, Dept. of 
Virology, Karolinska Institute, Stockholm, Sweden. 
2.4 Medium 
RPMI 1640 medium with L-glutamine (200 mM solution, 
1% by volume), benzylpenicillin (100 IU/ml), streptomycin 
sulfate (100 pg/ml), Hepes buffer (0.1 mM) and 10% 
heat-inactivated FCS was used for cell culturing. 
3 Results 
3.1 HIV-1 gag peptides affecting HLA-A2.1 expression 
on .174/T2 cells 
Peptides which caused elevation of MHC class I fluores- 
cence intensity (FI) by a factor of 2 or more, calculated with 
the formula given in Sect. 2.2, were considered as positive. 
We detected 6/39 positive peptides on HLA-A2.1. The 
quantified cytofluorimetric results are shown inTable 1 and 
Fig. l a .  
3.2 HIV-1 gag peptides affecting H-2 Dh, Kb or Db 
expression on RMA-S cells 
Of39 peptides 6 elevated the expression of Db molecules on 
RMA-S cells by a factor of two or more (Table 1 and 
Fig. 1 b). None of these positive peptides was identical or 
overlapping with those elevating the A2.1 levels on the 
.174/T2 line. Of 39 peptides 8 were found positive on Kb 
(Table 1, Fig. 1 c). Three of these, gag 14, 21 and 22 were 
positive on the HLA-A2.1 as well and one, gag 12 was 
positive also for Db and Dd. It is noteworthy that the latter 
peptide appeared to be cross-reactive with all the four 
MHC class I antigens as it was on the borderline of 
positivity (1.8) also for A2.1. 
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We found 2 of 39 peptides that elevated Dd expression at 
least with factor 2 (Tdble I). One of these, gag 27 enhanced 
the expression of the Dd molecule with a factor of 2.9 but 
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did not affect the other two murine MHC molecules at all 
and elevated only weakly the expression of the A2.1 
molecules (1.4). 
lo) HLA 2.1 binding peptides 
MGARASVLSG GELDRWEKIR LRPGGKKKYK LKHIVWASRE LERFAVNPGL 
f .  f .  
LETSEGCRQI LGQLQPSLQT GSEELRSLYN TVATLYCVHQ RIEIKDTKEA 
I '  I - * *  
LDKIEEEQNK SKKKAQQAAA DTGHSSQVSQ NYPlVQNlQG QMVHQAISPR 
f .  
TLNAWVKWE EKAFSPEVIP MFSALSEGAT PQDLNTMLNT VGGHQAAM 
- f *  
QMLKETINEEAA EWDRVHPVHA GPIAPGQMRE PRGSDIAGT S T Z G  
f f *  
WMTNNPPIPVGE IYKRWIILGL NKlVRMYSPT SILDIRQGPK EPFRDWDRF .
YKTLRAEQAS QEVKNWMTET LLVQNANPDC KTILKALGPA ATLEEMMT 
AC QGVGGPGHKA RVLAEMSQV TNTATIMMQR GNFRNQRKMV KCFNCG 
KEGH TARNCRAPRK KGCWKCGKEG HQMKDCTERQ A N F Z  
7SYKGRPGNF;LQSRPEPTAPPFLQSRPEPTAPPEESFRSGVE 
T'ITPPQKQEP IDKECYPLTS LRSLFGNDPS SQ 
(bl H-2 Db binding peptides 
MGARASVLSG GELDRWEKIR LRPGGKKKYK LKHIWASRE LERFAVNPGL 
LETSEGCRQI p a l  OPSl OT GSFFt RSLYN TVATLYCVHQ RIEIKDTKEA 
r 1 
LDKIEEEQNK SKKKAQQAAA DTGHSSQVSQ NYPIVQNIQG QMyHQAlSPq 
- 
TLNAWVIC/VE EKAFSPEVIP MFSALSEGAT PQDLNTMLNT VGPHQAAM, 
QM LKETINEEAA EWDRVHPVHA GPIAPGQMRE PRGSDIAGlT STLQEQIG .
WM TNNPPIPVGE IYKRWllLGL NKIVRMYSPT SILDIRQGPK EPFRDWDRF 
YKTLRAEQAS QEVKNWMTET LLVQNANPDC KTILKALGPA ATLEEMMTAC 
QGVGGPGHKA RVLAEMSQV TNTATIMMQR GNFRNQRKMV KCFNCGKE 
5 TARNCRAPRK KGCWKCGKEG HQMKDCTERQ ANFLGKIWPS YKGR 
PGNFLQ SRPEPTAPPF LQSRPEPTAP PEESFRSGVE TTPPQKQEP IDKE -
LYPLTS LRSLFGNDPS SQ -
3.3 Sensitivity of the method as compared with other 
techniques 
We have found that 15%, 21% and 15% of 39 HTV-1 gag 
peptides were positive on Db, Kh and A2.1, respectively, as 
detected by immunofluorescence. Using a quantitative 
assembly assay (immunoprecipitation with conformation- 
dependent mAb), Elvin et al. [6] found that 22%, 15% and 
14% of 49 HIV-1 gag peptides (of 15 aa average length, 
showing a 5 aa overlap with the neighboring ones) gave 
positive signals on Db, Kb and A2.1, respectively. This 
suggests that the sensitivities of the two methods are 
similar, and that they are more discriminative than the 
solid-phase plate binding assay which suggested that 44% 
of the HIV-1 gag peptides, identical to those used by Elvin 
et al., bound to A2.1 [4]. 
Icl H-2 Kb' binding peptides 
MGARASVLSG GELDRWEKIR LRPGGKKKYK LKHIWASRE LERFAVNPGL 
LETSEQCRQI LGQLQPSLQT GSEELRSLYN TVATLYCVHQ RIEIKDTKEA 
LDKIEEEQNK SKKKAQQAAA DTGHSSQVSQ NYPIVQNIQG QMYHQAISP? 
-- - 
TLNAWVKWE EKAFSPEVIP MFSALSEGAT PQDLNTMLNT VGGHQAAM 
1 -
QM LKETINEEAA EWDRVHPVHA GPIAPGQMRE PRGSDlAGm S T E Q  
IGWM TNNPPIPVGE IWKRWllLGL NKIVRMYSPT SILDIRQGPK EPFRDWD .
RF YKTLRAEQAS QEVKNWMTET LLVQNANPDC KTILKALGPA ATLEEMM 
TAC QGVGGPGHKA RVLAEMSQV TNTATIMMQR GNFRNQRKMV KCFNCG 
KEGH TARNCRAPRK KGCWKCGKEG HQMKDCTERQ ANFLGKIWPS YKG 
RPGNFLQSRPEPTAPPFLQSRPEPTAP PEESFRSGVETITPPQKQEP 
IDKELYPLTS LRSLFGNDPS SQ 
Figure 1.  Ability of overlapping synthetic peptides to enhance 
expression ol MHC class I molecules. (a) HLA-A2.1; (b) H-2 Dh; 
(c) Kb, assessed by indirect immunofluorescence (solid symbols 
above the sequence) and by the in vitro assembly assay [6] (open 
symbols below the sequence). Peptides which caused elevation of 
MHC class I fluorescence intensity (FI) by a factor of 2 or more. 
calculated with the formula given in Sect. 2.2 and peptidcs 
increasing thc concentration of the folded heavy chains more than 
three standard deviations from the control were considered as 
positive in the immunofluorescence and in vitvo assembly assays, 
respectively. Bold letters mark motifs of peptides binding to the 
relevant MHC class I molecules, predicted by computer searching 
based on published motifs [33]. Asterisks mark the first amino acid 
of the motifs. 
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3.4 EBV peptides affecting HLA-A2.1 expression on from LMP (Table 2). Five of them elevated the expression 
of Kb as well, but had no effect on A2.1 and Dd. Of 16 
peptides screened on Kb 5 were positive. One was derived 
from EBNA-2,3 from EBNA-3 and 1 from EBNA-6. They 
elevated also Dh expression, but had no effect on A2.1 and 
Dd (Table 2). Seventeen peptides were also tested on the 
RMA-S Dd transfectant. One, BSLF2 1-13 was positive 
without cross-reactivity for the other included class I 
antigens (Table 2). 
the .174/T2 cells 
Thirty-two peptides derived from EBV-associated proteins 
wcre screened for the capacity to interact with HLA-A2.1. 
One of them, the EBNA-1-derived peptide 107 elevated 
the expression of HLA-A2.1 molecules by more than factor 
2 (Table 2). 
3.5 EBV peptides affecting H-2 Db, Kb or Dd expression 
on RMA-S cells 3.6 Comparison of the positive peptides with motifs for 
the respective MHC class 1 molecules 
Of the 16 screened peptides 7 were found positive for 
induction of lS' expression. One of them was derived from 
EBNA-2, 4 from EBNA-3, 1 from EBNA-6 and 1 derived 
We made a computer searching for A2.1, Db and Kb binding 
nonamers in the HIV-1 gag protein based on the published 
Table 1. Effect of overlapping peptides spanning the HIV-1 gag protein on the expression of MHC class I molecules on cells of the peptide 
loading dcficient human .174/T2 (HLA-A2.1) line, murine RMA-S line (H-2 Dh and Kh) and its transfectant with the Dd gene 
MHC class I expression 
Peptide 
1 MGARASVLSGGELDRWEKIRLR 
2 ELDRWEKIRLRPGGKKKYKLKHIV 
3 PGGKKKYKLKHIVWASRELERFAV 
1 WASRELERFAVNPGLLETSEGCRQ 
5 NPGLLETSEGCRQILGQLQPSLQT 
6 ILGQLQPSLQTGSEELRSLYNTVA 
7 SEELRSLYNTVATLYCVHQRIEIK 
8 LYCVHQRIEIKDTKEALDKIEEEQ 
9 TKEALDKIEEEQNKSKKKAAAA 
10 NKSKKKAQQAA ADTGHSSQVSQNY 
11 TGHSSQVSQNYPIVQNIQGQMVHQ 
12 PIVQNIQGQMWHQAISPRTLNAWVK 
13 AISPRTLNAWVKVVEEKAFSPEVI 
14 VVEEKAFSPEVIPMFSALSEGAT 
15 MFSALSEGATPQDLNTMLNTVGG 
16 PQDLNTMLNTVGGHQAAMQMLKET 
17 HQAAMQMLKETINEEAAEWDRVH 
18 INEEAAEWDRVHPVHAGPIAPGQM 
19 PVHAGPIAPGQMREPRGSDIAGTT 
20 FEPRGSDIAGTTSTLQEQIGWMTN 
21 STLQEQIGWMTNNPPIPVGEIYKR 
22 NPPIPVGEIYKRWIILGLNKIVRM 
23 WIILGLNKIVRMYSPTSILDIRQG 
24 YSPTSILDIRQGPKEPFRDY VDRF 
25 PKEPFRDY VDRFYKTLRAEQASQE 
26 YKTLRAEQASQEVKN WMTETLLVQ 
27 KNWMTETLLVQNANPDCKTILKALG 
28 ANPDCKTILKALGPAATLEEMMTA 
29 AATLEEMMTACQGVGGPGHKARVL 
30 GVGGPGHKARVLAEAMSQVTNTAT 
31 AEMSQVTNTATIMMQRGNFRNQR 
32 MMQRGNFRNQRKMVKCFNCGKEGH 
33 MVKCFNCGKEGHTARNCRAPRKKG 
34 TARNCRAPRKKGCWKCGKEGHQMK 
35 WKCGKEGHQMKDCTERQANFLKGI 
36 CTERQANFLGKI WPSYKGRPGNFL 
37 PSYKGRPGNFLQSRPEPTAPPELQ 
38 SRPEPTAPPFLQSRPEPTAPPEES 
39 RPEPTAPPEESFRSGVETTTPPQK 
40 RSGVETITPPQKQEPIDKELYPLT 
41 EPIDKELYPLTSLRSLFGNDPSSQ 
MP 57-68 K62 KGILGKVFTLTV" 
NP 345-360 SFIRGTKVSPRGKLS'P) 
NP 365-279 IASNENMDAMESSTLe) 
A2.1 
I .o") 
1.3 
1.3 
1.1 
1.7 
1.1 
1.5 
1.9 
Toxic 
2.2 
1.9 
1.8 
2.2 
2.3 
1.9 
1.8 
1.9 
1.5 
0.8 
1.7 
2.3 
2.0 
1.6 
1.3 
1.1 
1.1 
1.4 
1.5 
1.4 
0.7 
0.5 
1.2 
Toxic 
0.2 
1 .1  
2.8 
1.4 
1.5 
1.4 
1.6 
1.8 
4.9 
1 .0 
1.2 
__ 
-
-
-
-
-
-
D 
1.3 
1.8 
1.9 
1.8 
1.0 
2.lh' 
1.2 
1.2 
1.3 
1.9 
2.4 
1.1 
1 .0 
1.2 
1.1 
1.4 
1.2 
1.1 
1.2 
1 .0 
1.2 
1.2 
1.3 
1.3 
1.1 
1.0 
0.8 
0.8 
1.1 
1.1 
2.5 
1 .0 
1.1 
1.1 
1 .o 
1 .o 
2.0 
2.0 
2.0 
1 .0 
1 .0 
5.6 
-
-
-
-
-
-
-
K b  
1.6 
1.9 
2.2 
1.8 
1.5 
1.4 
1.3 
1.5 
1.9 
1.5 
2.5 
1.4 
2.0 
1.9 
1.6 
2.0 
1.8 
1.9 
2.2 
2.1 
2.0 
2.0 
1.3 
1 .0 
1.3 
1.0 
0.8 
0.8 
1.1 
1.8 
1.2 
1.2 
0.9 
0.8 
1.2 
1.2 
1 .0 
1.1 
1 .0 
1.1 
3.9 
1.1 
-
-
-
-
-
-
-
-
-
Dd 
1 .0 
0.9 
1 .0 
0.7 
0.7 
1.0 
1.5 
1.4 
1.2 
0.6 
2.2 
0.7 
0.6 
1 .o 
1 .0 
0.8 
1.4 
1.2 
0.8 
1.1 
1 .0 
1.4 
1.8 
1.4 
2.9 
1.0 
1.5 
1.1 
0.9 
1.2 
0.8 
1.4 
1 .o 
1.5 
1.2 
1.3 
1.2 
1.1 
0.9 
1.1 
1.0 
0.8 
-
a) The results were calculated on the 
basis of fluorescence intensity (FI): 
Frsarnp'c where sample means peptide 
FICOlltrOl 
treated cells and control means cells 
without peptide. 
b) Peptides which elevated the fluores- 
cence intensity with a factor of 2 or 
more were classed as positives (under- 
lined). 
c) Influenza matrix protein peptide K62, 
included as control for HLA-A2.1 
binding. 
d) Influenza nucleoprotein peptide. con- 
trol for Kh binding. 
e) Influenza nucleoprotein peptide, con- 
trol for D" binding. 
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motifs for these allele products [33]. Thirty-one A2.1 
binding motifs were found, distributed in 23 peptides in our 
HIV-1 gag peptide panel (Fig. 1 a). Two of the six peptides 
which elevated A2.1 expression with factor 2 or more 
included such motifs. Of the 23 peptides including 
motif(s)l4 (61%) caused elevation of A2.1 expression with 
a factor of 1.5 or more. On the other hand 6 of the 16 
peptides (38%) without motif elevated A2.1 expression 1.5 
or more.The finding that both the overlapping HIV-1 gag 
11 and 12 peptides elevated A2.1, could be explained by the 
relevant motif included into the overlapping part of the 
both peptides. 
Six Db binding motifs were predicted in the HIV-1 gag 
protein distributed in 5 peptides in our panel (Fig. 1 b). 
One of the 6 peptides in our panel, which elevated Db 
Table 2. Effect of peptides derived from EBV-encoded proteins on the expression of MHC class I molecules on cells of the deficient 
human .174/T2 (HLA-A2.1) line, murine RMA-S line (H-2 Db and Kh) and its Dd transfectant 
MHC class I expression 
Peptide 
Latent Proteins 
EBNA-1 
EBNA-1 
C-term 
A2.1 Db Kd Dd 
AIKDLVMTKPAPTCNIRV- 
TVCSFDDGV 
AGGAGG 
CRARGRGRGAGEKRPM 
RGGSRERARGRGRGR- 
GEKRP 
RGRGRGEKRPRSPSSQSSSS 
AGAGGGAGGAGAGGG- 
1.4") 0.9 1.1 
2.1 -b) - 
1.1 - - 
1.1 - - 
-
1.5 
- 107 
108 
EBNA-1, 5 
- 
0.8 
0.9 EBNA-1, 6 
EBNA-2 
EBNA2a 
1.0 - - 
PRRPEPNTSSPSMPELSPVLG- 
LHQGQ 
PPRPTRPTTLPPIPLLIC 
PPGVINDLHHL 
LDESWDYEFETT 
1.0 - - 
116 (213-23OC) 
TB3 (305-317) 
TBl (454-465) 
EBNA-3 
68B 
68G 
EBNA3EBV. 1 
(334-348) 
(339-353) 
EBNA-3lEBV.2 
EBNA-4 
203 
EBNA-5 
180 
1 87 
188 
EBNA-6 
1.0 - - 
1.2 5.5 2.0 
1.5 1.7 0.9 
- -  
AWN AGFLRGRAYGID 
AWNAGFLRGRAYGLD 
AWNAGFLRGRAYG 
1.8 3.9 1.5 
1.3 4.4 2.9 
0.9 2.3 2.4 - -  
0.8 
0.8 
1.1 
1.1 FLRGRAYGHDLLRTE 0.9 2.9 - -  2.3 
PAPQAPYGYQEP 1.3 - - 
PRGDRSEGPGPTRPGPPG 
GQEPRRVRRRVLV 
EEEEVVSGSPSG 
1.6 - - 
1.3 - - 
1.0 - - 
KEHVIQNAFRK 
EENLLDFVRFMGVMSSCNNP 
- 0.7 - 
- 4 . 1 %  
0.9 
0.7 
1.5 
- 
- 
0.9 
- 
- 
- 
- 
77 
LMP 
Lydma-1 (42-53C) 
Lydma-4 (125-132) 
Lydma-S (159-171) 
TB2 (321-331) 
TB2a (321-331) 
1-18 
138 (188-205C) 
405 (43-53) 
IVMSDWTGGALLC 
VMSDWTGGALL 
LLEMLWRLGATL 
Y LN W WTLLVDL 
PQLTEEVENRG 
PQLTEEVENR 
MEHALERGPGPRRPPGRC 
GQRHSDEHHHHDDSLPHPQC 
1.6 1.7 1.6 
1.4 - - 
0.8 1.7 1.7 
0.8 1.5 1.0 
1.2 - 2.4 1.5 
1.4 0.5 1.0 
- 1.0 - 
1.3 - - 
Proteins of the lytic cycle 
BcLFl (327-352) VMRTFGEHMARIVDSPEIC- 
AGSTKSDL 
BILF2 (K4, 48-69) VSRIELGRGYTPC 
BZLFl 2. exon LEIKRY KNRVASKC 
BSLF2 (1-13) HVPSQLRSRTSSL 
BALF4 (266-278) GTNPQGERRATLDC 
BALF4 (675-688) RKDLDN AVSNGRNQC 
0.7 0.9 1.1 1.1 
1.0 
1 .o 
2.0 
0.9 
1.0 
-
a) Results were calculated as in Table 1. 
b) -: not tested. 
1.1 1.2 1.2 
1.1 1.0 1.0 
1.1 - 
0.6 - - 
1.2 - - 
- 
2702 
expression with a factor 2 or more included two such motifs. 
Of the 5 peptides 2 (400/) which included motif(s) and 8 of 
the 34 peptides (24%) without motif(s) elevated Dh 
expression more than 1.5 times. 
Four K”-binding motifs were predicted, distributed in 4 
peptides in our panel (Fig. 1 c). Of the 8 peptides positive in 
our assessment 1 included Kb binding motif. Of the 4 
peptides 2 (50%) including Kb motifs and 16 of the 31 
peptides (52%) without motifs elevated Kh expression 
more than 1.5 times. 
G. Stubcr, S. Modrow, P. Hoglund ct al. Eur. J. Immunol. 1992. 22: 2697-2703 
with the assembly assay with comformation-dependent 
antibody [6]. The two different sets of peptides derived 
from the HIV-1 gag protein screened by Elvin et al. [6] and 
our group opens the possibility of mapping shorter 
sequences from overlapping peptides found positive in the 
both assessments (Fig. la-c). More than the half of the 
positive peptides were identified as positives in both assays, 
but many were positive only in one assay. We have used 24 
aa long HIV gag peptides which should be compared with 
reservation with those of 15 aa long peptides screened in the 
in vitro assembly assay by Elvin et al. In vivo presented 
“natural” peptides are 8-9 aa long [33, 36-38]. The 
suboptimal 24 aa length of our peptides may explain the 
observation that none of the HIV-1 gag peptides had as high 
capacity to enhance class I expression as the shorter control 
influenza peptides (2-2.9 times and 3.9-5.6 times eleva- 
tion, respectively; Table 1). It may also explain why only 
two of the four known A2.1-restricted CTL epitopes 
derived from HIV gag protein [39], FLQSRPEPT and 
AMQMLKE, present in HIV-1 gag peptide 38 and 11, 
respectively, elevated A2.1 expression with a factor of 1.5 
or more. The remaining two, PIAPQMRE and 
QMKDCTERQ, present in HIV-1 gag peptides 19 and 35 
did not change A2.1 expression. The shorter sequence of 
the EBV peptides included in our study compared to the 
HIV- 1 gag peptides may explain the higher average binding 
capacity of the positive EBV peptides (compare Tables 1 
and 2). 
Although HPLC-purified and sequenced peptides were 
used we can not exclude contamination by shorter 
sequences which may be responsible for the elevation of 
MHC class I levels. MHC molecules were indeed shown to 
accumulate the shorter byproducts of synthetic peptides 
[40,41]. That could also explain why peptides overlapping 
positive ones often elevated class I expression. Cerundolo 
et al. [42] have shown that longer variants of an H- 
2 Kb-binding nanomer had 100-fold faster off-rates and 
Christinck et al. [43] have detected a dissociation rate for 
the natural influenza NP 366-374 peptide which was three 
orders of magnitude lower than that of the longer NP 
Y365-380 version. This does not exclude binding by longer 
peptides. It is also possible that the longer peptides used in 
this study had been trimmed to appropriate binding length 
after binding to the class I molecules as suggested [44,45]. 
Recently, Sherman et al. [46] showed that proteolytic 
enzymes naturally present in serum may cleave longer 
synthetic peptides to shorter ones which have a class I 
binding capacity. On the other hand Henderson et al. and 
Wei et al. [47, 481 found recently that HLA-A2.1 bound 
peptides which are longer than nanomers can be eluted 
from the T2 cells. Such peptides bind to the A2.1 with 
affinities similar to those of nanomers [47]. 
4 Discussion 
Using immunof’luorescence detection of elevated MHC 
class I levels as a method for assessing peptide binding, we 
have found that, for any tested H-2 or HLA allele, between 
5% and 21% of the HIV-1 gag peptides, and between 6% 
and 43% of EBV peptides were scored as positive. The 
strength of the peptide-MHC class I interactions showed a 
continuous distribution. Three HIV-1 peptides interacted 
with two different MHC class I molecules and one elevated 
the expression of all the four tested MHC class I molecules. 
Five latent protein peptides (derived from EBNA-2, 3 and 
6) gave positive results on two different MHC molecules 
and one (Lydma-1 derived from LMP) appeared to have a 
broad cross-reactivity. showing intermediate binding to all 
the four molecules.The peptide KRWIILGLNKIVRM has 
been shown to be B27 specific [34]. We now show, that the 
same sequence (HIV-1 gagpeptide22/23) binds toA2.1 and 
Kh,  suggesting similar binding capacity of these human and 
murinc MHC molecules. We have detected human mouse 
cross-reactivity also between A2.1 and Kh with the HIV-1 
gag peptides 14, 21 and 22. It may be interpreted with 
similarities between these two MHC molecules. Peptide 14 
but not 21 and 22 included both A2.1- and Kb-binding 
motifs. HIV-1 gag peptide 12 was found to bind to all the 
three murine MHC class I molecules investigated in this 
study and has shown binding to the human A2.1 also near to 
the criteria of positivity. This could reflect nondiscrimina- 
tive binding properties or could suggest, that similarities in 
peptide binding characteristics between humadhuman, 
human/mouse or mouse/mouse may depend on the peptide 
sequence. No human/mouse cross-reactivity was detected 
with peptides from EBV proteins, included in this study, 
although the EBNA-3-derived 68B peptide which was 
positive for the murine Dh,  elevated the expression of the 
human A2. I I .8 times, near to the criterion of positivity. 
This peptide was previously shown to serve asTcell epitope 
for A-type virus specific, B8-restricted CTL [27]. For this 
peptide. wc have detected a binding capacity to Db and Kb 
molecules higher than the average of all the included 
peptides. Thorley-Lawsson et al. [35] has shown that one 
Tcell clone generated with LMP 43-53 peptide was 
HLA-A1 restricted, which could suggest binding of this 
peptide to A1.With a near variant of this peptide, Lydma-1 
(LMP 42-53) we have detected enhancement of all the four 
class I molecules. Thus, it appears that peptides 68B and 
LMP 42-53 show cross-reactivity between several human 
and mouse class I molecules. Of 16 EBV peptides 5 have 
shown mouse/mouse cross-reactivity between Db and Kb. 
The lower proportion of HIV-1 peptides binding to A2.1 as 
compared to the solid-phase assay (3-5) is in accordance 
Our results suggest that the presence of the published 
A2.1-, Db- and Kb-binding motifs are not always sufficient 
for interaction of the peptide with the respective MHC 
molecules. Only one of the six Db and one of the eight 
Kh-positive peptides included motif for the respective MHC 
molecule. A higher proportion of the HIV-1 gag peptides 
including Db binding motifs elevated Dh expression with a 
factor of 1.5 or more than those without motifs (40% and 
24%, respectively). This was not the case with peptides 
interacting with Kh (50% of peptides with motifs and 52% 
of peptides without motifs elevated Kb by a factor 1.5 or 
Eur. J. Immunol. 1992. 22: 2697-2703 Assessment of peptide interaction with MHC class I molecules 2703 
more). Of the 16 peptides 6 (38%) elevated A2.1 expres- 
sion with a factor of 1.5 or more.The suboptimal length of 
the peptides may explain that a proportional of peptides 
including motifs did not interact with the relevant MHC. 
The binding of peptides without motifs suggests, however, 
that further identification of motifs may be required. 
The use of viable cells gave us a possibility to test the 
relevance of the results in cell lysates. The presented 
method may allow a first screening of large numbers of 
peptides to judge their feasibility as T cell epitopes. 
Received March 3, 1992: in final rcviscd form June 24, 1992. 
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